In 2023, Denise “Necee” Regis was brought face to face with her old art studio building on Brookline Avenue. As she walked by, she was able to identify the window that belonged to the room where she once spent the late 70s and early 80s working on a Master of Fine Arts at the Massachusetts … Read more
Dana-Farber physician-scientists presented results of more than 100 research studies at the 66th American Society of Hematology (ASH) annual meeting. Scientists shared findings across a range of hematologic disorders, underscoring the Institute’s dedication to innovation in hematologic oncology research, advances in early disease detection and intervention, and improving patient outcomes. ASH is the world’s most comprehensive hematology … Read more
Over the last decade, significant strides have been made in understanding the molecular underpinnings of acute myelogenous leukemia (AML) in adults, which has led to better drugs and better treatment outcomes for patients. This shifting landscape now makes it possible for cancer researchers and providers to ask, “How can we do better?” Dana-Farber medical oncologist … Read more
Naomi Dogan, PhD, still remembers a visit to the hospital earlier this year for blood work, after joining a clinical trial for patients incurring symptoms related to polycythemia vera — one of a group of rare blood disorders known as myeloproliferative neoplasms (MPNs). In a far corner of the large room a machine quietly hummed … Read more
Kathy Giusti was driving in rush hour traffic one January day in 1996 when her doctor called and requested they meet the next morning about her recent blood tests. Alarmed, Giusti insisted on more details, and the doctor eventually shared his concerns that she may have multiple myeloma. Giusti’s response to this news was quick … Read more
Jim Omel, MD, helped many cancer patients during his long career as a family physician, and that has not changed since his own 1997 diagnosis with multiple myeloma. What has changed is the reach of his support. While Omel, 77, cared for primarily farming families near his Nebraska clinic during 25-plus years in practice, his … Read more
Multiple myeloma is a cancer of the bone marrow. It affects plasma cells, which are mature forms of blood cells called B-lymphocytes. In the case of multiple myeloma, abnormal plasma cells build up in the bone marrow, and can cause anemia. In addition, multiple myeloma may cause kidney problems, bone injury and fractures. There have … Read more
While hematological cancers like leukemia, lymphoma, and multiple myeloma involve white blood cells, other, rarer hematologic malignancies affect red blood cells and platelets. These include polycythemia vera, in which the bone marrow produces too many red blood cells, and essential thrombocythemia, in which platelets levels are abnormally high. Both are chronic diseases that can usually … Read more
Patricia Smith’s experience with cancer will stay with her for the rest of her life. “Walking through deep waters changes you,” she says. “You’re still the same person, but you’re different.” In 2009, Smith was diagnosed with B-cell diffuse lymphoma after she experienced weeks of fatigue and found a lump under her right arm. She … Read more
Follicular lymphoma is a slow-growing form of non-Hodgkin lymphoma (NHL) that arises in white blood cells called B lymphocytes. It’s named for the clumps of abnormal B cells, called follicles, that develop in patients’ lymph nodes. It accounts for 20-30% of all cases of NHL. Although follicular lymphoma currently isn’t curable, patients can live with … Read more
Bispecific antibody therapies are a type of immunotherapy for patients with B-cell non-Hodgkin lymphoma. These therapies provide a valuable new option for patients. There are many standard therapies that are monoclonal antibodies. These therapies treat cancer by binding to a marker on cancer cells and rallying the immune system to destroy them. Bispecific antibodies are … Read more
BCL2 inhibitors are drugs that prompt cancer cells to die by altering the interactions among key proteins within the cells. They were clinically developed, in large part, by researchers at Dana-Farber and have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia … Read more
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, diagnosed in more than 18,000 people in the U.S. every year. It is a fast-growing lymphoma that can arise in the lymph nodes or, more rarely, in organs such as the spleen, liver, and others. As its name indicates, DLBCL involves the … Read more
Throughout the 20 years Robert Jenkins has been living with follicular lymphoma, he has been through many different treatments — from traditional chemotherapy protocols to innovative approaches like CAR T-cell therapy and bispecific antibodies. His lengthy survivorship has allowed Jenkins to benefit from new advances as they’ve emerged, and along with his wife, Lorna, one … Read more
When Youling Sun was diagnosed in Shanghai, China, with acute myeloid leukemia (AML) in 2018, he called his son, Conghao, in Boston, for advice. His son’s message was unequivocal: Come to Boston for your treatment. Today, Sun, a retired office worker from Shanghai, has multiple reasons to be thankful he took that advice — both … Read more
A pair of subversives, the genes BTK and PLCG2 are often mutated in chronic lymphocytic leukemia (CLL) that is resistant to the drug ibrutinib. But how common are these genetic alterations and to what extent do they contribute to ibrutinib resistance? The answers will help doctors determine which targeted therapies are most likely to help … Read more
As a systems operator who works to help maintain the electrical grid for New York state, Brian Houlihan, 46, is used to getting power to the people. But when the multiple myeloma he has lived with since 2011 stopped responding to chemotherapy, it was Houlihan who needed a recharge. He got it, through an innovative … Read more
Waldenström macroglobulinemia, a rare form of non-Hodgkin lymphoma, has its share of eccentricities. One of the hallmarks of the disease, for example, is an overabundance of a particular protein, yet other conditions may also have that feature. It’s also not unusual for patients to have very high protein levels but have no symptoms or mild … Read more
David Trueblood’s long career in journalism was shaped by new technology, including the rise of digital photography and the impact of online media. So, upon learning in early 2023 that he would need a stem cell transplant due to myelodysplastic syndrome (MDS), a rare blood disorder impacting his bone marrow, Trueblood appreciated the role innovation … Read more
Michelle Karalekas’ time in the Mont Tremblant Ironman Triathlon in Quebec on Aug. 20 — 14 hours, 5 minutes — was not her fastest in the grueling event, but it may have been her most impressive. It was the first time she’d competed since undergoing a stem cell transplant for acute myeloid leukemia (AML) almost … Read more